-
公开(公告)号：US20220402912A1
公开(公告)日：2022-12-22
申请号：US17319231
申请日：2021-05-13
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Gaston Andre Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： C07D471/04 , A61K31/519 , C07D413/14 , C07D401/14 , C07D405/04 , C07D401/04 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US09409907B2
公开(公告)日：2016-08-09
申请号：US14426549
申请日：2013-09-09
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： A01N43/90 , A61K31/519 , C07D471/00 , C07D487/00 , C07D471/04 , C07D401/14 , C07D413/14 , C07D401/04 , C07D405/04 , C07D519/00
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
摘要翻译： 本发明涉及式Ⅰ化合物，其中R 1，R 4，Ar，W，X和Z全部如本文所定义。 已知本发明的化合物通过与Mps1激酶本身的相互作用直接或间接地抑制单轴1（Mps1，也称为TTK）激酶的心轴检查点功能。 特别地，本发明涉及这些化合物作为治疗和/或预防增殖性疾病如癌症的治疗剂的用途。 本发明还涉及制备这些化合物的方法以及包含它们的药物组合物。
-
公开(公告)号：US11897877B2
公开(公告)日：2024-02-13
申请号：US17319231
申请日：2021-05-13
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Gaston Andre Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： C07D471/04 , C07D401/14 , C07D413/14 , C07D401/04 , C07D405/04 , C07D519/00 , A61K31/519
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I
wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.-
公开(公告)号：US20160222009A1
公开(公告)日：2016-08-04
申请号：US15091887
申请日：2016-04-06
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： C07D471/04 , C07D519/00 , C07D401/04 , C07D405/04 , C07D401/14 , C07D413/14
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US20160220570A1
公开(公告)日：2016-08-04
申请号：US15091980
申请日：2016-04-06
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： A61K31/519
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US11046688B2
公开(公告)日：2021-06-29
申请号：US16598717
申请日：2019-10-10
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Gaston Andre Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： A61K31/519 , C07D471/04 , C07D401/14 , C07D413/14 , C07D401/04 , C07D405/04 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US10479788B2
公开(公告)日：2019-11-19
申请号：US15864499
申请日：2018-01-08
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： A61K31/519 , C07D471/04 , C07D401/14 , C07D413/14 , C07D401/04 , C07D405/04 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US09834552B2
公开(公告)日：2017-12-05
申请号：US15091980
申请日：2016-04-06
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： A01N43/90 , A61K31/519 , C07D471/04 , C07D401/14 , C07D413/14 , C07D401/04 , C07D405/04 , C07D519/00
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US20200165241A1
公开(公告)日：2020-05-28
申请号：US16598717
申请日：2019-10-10
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Gaston Andre Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： C07D471/04 , A61K31/519 , C07D519/00 , C07D405/04 , C07D401/04 , C07D413/14 , C07D401/14
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
公开(公告)号：US20180141944A1
公开(公告)日：2018-05-24
申请号：US15864499
申请日：2018-01-08
发明人： Swen Hoelder , Julian Blagg , Savade Solanki , Hannah Woodward , Sebastien Naud , Vassilios Bavetsias , Peter Sheldrake , Paolo Innocenti , Kwai-Ming J. Cheung , Butrus Atrash
IPC分类号： C07D471/04 , A61K31/519 , C07D519/00 , C07D401/14 , C07D401/04 , C07D413/14 , C07D405/04
CPC分类号： C07D471/04 , A61K31/519 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/14 , C07D519/00
摘要： The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.036 秒)
